FDA issues emergency use authorization (EUA) for casirivimab and imdevimab combination for treatment of mild to moderate COVID-19 in adults and children

EUA based on results from trial of 799 patients with COVID-19 at high risk for disease progression, which showed that administration of casirivimab and imdevimab reduced COVID-19-related hospitalisation/emergency admissions within 28 days after treatment vs placebo [3% vs 9%].

Source:

Biospace Inc.